annual
epidem
influenza
viru
infect
respons
consider
morbid
mortal
pandem
much
devast
consider
knowledg
viral
infect
replic
acquir
mani
detail
still
elucid
viru
remain
challeng
target
drug
design
develop
review
provid
overview
antivir
drug
target
influenza
viral
replic
cycl
includ
brief
descript
chemic
synthes
biolog
activ
review
see
replic
cycl
influenza
viru
offer
sever
virusspecif
event
could
consid
target
chemotherapeut
intervent
fig
figur
appar
replic
cycl
influenza
viru
could
interrupt
sever
stage
viru
attach
cell
mediat
interact
hemagglutinin
ha
receptor
cell
surfac
ii
endocytosi
fusion
viral
envelop
cell
membran
iii
uncoat
viral
particl
within
endosom
follow
penetr
h
ion
matrix
ion
channel
interior
virion
iv
transcript
viral
rna
genom
messeng
rna
polymeras
complex
pa
v
translat
mrna
viral
protein
vi
packag
bud
progeni
viru
particl
cell
surfac
result
vii
releas
progeni
virion
allow
spread
viru
infect
figur
site
chemotherapeut
intervent
highlight
amantadin
sirna
short
interf
rna
neuraminidas
inhibitor
review
differ
antiinfluenza
viru
agent
function
interact
differ
target
within
viral
replic
cycl
inhibit
bind
ha
epitheli
cell
could
effici
mean
block
infect
crystal
structur
ha
complex
variou
deriv
sialic
acid
determin
knowledg
led
ration
design
carbohydratebas
inhibitor
ha
collectin
also
bind
viral
ha
probabl
prevent
infect
interf
cellular
bind
activ
ha
effect
strategi
take
advantag
natur
interact
viru
receptor
depend
thermodynam
advantag
offer
engag
multipl
simultan
bind
interact
whilst
bival
sialic
acid
ligand
provid
advantag
potent
effect
sialic
acid
receptor
antagonist
shown
activ
vitro
incorpor
sialic
acid
moieti
onto
polymer
templat
strategi
use
advantag
natur
structur
physic
properti
templat
employ
project
sialic
acid
residu
import
hydrophob
compon
appear
necessari
high
affin
bind
exampl
heptasaccharid
deriv
rather
complex
bival
ligand
inhibit
influenza
viru
adsorpt
erythrocyt
hemagglutin
ic
mm
wherea
structur
simpler
dimer
ligand
inhibit
hemagglutin
ic
mm
branch
dendrit
like
amino
acid
backbon
cap
sialic
acid
moieti
afford
molecul
cluster
residu
effect
inhibitor
hemagglutin
erythrocyt
altern
approach
focus
incorpor
differ
concentr
sialosid
lipid
liposom
follow
irradiationinduc
polymer
follow
synthet
converg
methodolog
three
differ
famili
compound
vari
linker
span
length
gener
peracetyl
methylnacetylbdneuramin
afford
turn
convert
sialosid
treatment
hg
cn
follow
oxid
kmno
scheme
molecul
made
exampl
ethylen
glycol
scheme
synthesi
sidechain
seri
exemplifi
synthesi
sidechain
seri
bear
peptid
linkersderiv
glycin
exemplifi
n
scheme
final
also
ureabas
linker
contain
piperazin
unit
investig
synthesi
sidechain
seri
exemplifi
p
q
scheme
influenza
viru
ha
synthes
singl
polypeptid
precursor
ha
cleav
ha
ha
subunit
host
proteas
proteolyt
cleavag
ha
virion
surfac
essenti
infect
three
influenza
type
b
c
therefor
probabl
vulner
antivir
intervent
proteolyt
inhibitor
shown
possess
antiinfluenza
activ
mice
addit
pulmonari
surfact
may
act
endogen
inhibitor
proteolyt
activ
influenzaa
ha
proteas
inhibitor
eaminocapro
acid
eaca
decreas
viru
replic
lung
influenzachalleng
mice
mechanist
studi
eaca
proteas
mice
infect
influenza
viru
suggest
compound
may
act
least
part
inhibit
ha
cleavag
influenza
viru
believ
enter
mammalian
cell
endocytosi
clathrinco
pit
viru
fuse
endosom
membran
irrevers
conform
chang
ha
molecul
caus
lower
vesicl
ph
action
atpdepend
h
pump
inhibit
fusion
influenza
virus
specif
dock
hydrophob
pocket
around
fusion
peptid
initi
survey
sar
associ
salicycl
acid
element
indic
essenti
role
reveal
limit
toler
addit
substitu
except
lipophil
substitu
ch
cl
f
cf
afford
potent
antivir
agent
ec
correl
inhibit
hemolysi
howev
polar
function
group
specif
cn
co
afford
analog
consid
inact
salicylamid
deriv
obtain
heat
cyclic
acetonid
simultan
protect
well
acid
phenol
moieti
correspond
amin
toluen
altern
deriv
prepar
condens
correspond
acid
chlorid
amin
et
ndmap
treatment
lawesson
reagent
yield
correspond
thioamid
scheme
mixtur
amid
diastereom
analog
chloro
deriv
exhibit
ec
mgml
inhibit
influenza
infect
cell
cultur
potent
inhibitor
seri
prove
axial
thioamid
ec
mgml
whilst
equatori
isom
inact
concentr
half
maxim
cytotox
concentr
cc
mgml
structur
similar
compound
wyethayerst
also
found
fusion
inhibitor
influenza
aviru
compound
activ
ic
mgml
ic
mgml
viru
ic
mgml
tertbutylhydroquinon
congen
design
block
conform
chang
ha
molecular
dock
programm
howev
ha
protein
shown
becom
resist
proteolyt
action
trypsin
thermolysin
proteinasek
treatment
fusion
inhibitor
endosom
acidif
prevent
rel
unsophist
fashion
agent
act
gener
base
buffer
gradual
declin
ph
typic
basic
amin
deriv
effect
concentr
high
consid
physiolog
relev
exampl
millimolar
concentr
antiparkinson
agent
norakin
chloroquin
thought
function
fashion
contrast
stabil
ha
low
ph
compound
abl
destabil
neutral
ph
caus
inactiv
conform
chang
endosom
entri
seri
podocarp
acid
interact
ha
neutral
ph
prevent
low
phinduc
chang
fusogen
conform
compound
similarli
effect
influenza
virus
less
activ
influenza
b
virus
mice
infect
lethal
challeng
influenza
compound
gave
surviv
rate
respect
intraperiton
dose
mgkg
bid
day
novel
antivir
protein
cyanovirinn
cvn
initi
discov
base
potent
activ
human
immunodefici
viru
hiv
remark
howev
cvn
relat
homolog
show
highli
potent
antivir
activ
almost
strain
influenza
b
viru
includ
clinic
isol
neuraminidas
inhibitorresist
strain
ec
mg
ml
influenza
viru
particl
pretreat
cvn
viral
titer
lower
significantli
studi
identifi
influenza
viru
hemagglutinin
target
cvn
show
antivir
activ
hemagglutinin
bind
correl
indic
cvn
interact
hemagglutinin
involv
oligosaccharid
howev
fusion
inhibitor
appear
narrow
spectrum
activ
influenza
virus
determin
molecular
mechan
action
adamantan
allow
ration
develop
addit
inhibitor
ion
channel
amantadin
establish
effect
prophylaxi
treatment
influenza
viru
infect
although
initi
licens
clinic
use
adamantin
limit
central
nervou
system
cn
side
effect
current
interest
inhibitor
led
develop
new
highli
potent
compound
also
prompt
optim
synthesi
amantadin
rimantadin
kochcarbonyl
known
transform
carbon
monoxid
alcohol
olefin
water
carboxyl
acid
howev
reaction
usual
carri
sever
condit
high
co
pressur
high
temperatur
strong
acid
condit
therefor
much
attent
focus
conveni
environment
benign
process
synthet
rout
prepar
nonsymmetr
keton
reaction
acyl
chlorid
correspond
grignard
reagent
presenc
catalyt
amount
metal
halid
previous
describ
literatur
reaction
condit
optim
effici
cheap
fast
method
prepar
adamantyl
keton
novel
amantadin
rimantadin
deriv
synthes
evalu
kolocouri
et
al
new
adamantan
deriv
found
inhibit
replic
influenza
aviru
ec
antivir
effect
concentr
mgml
spiro
adamantan
mgml
spiro
adamantan
mgml
spiro
adamantan
mgml
pyrrolidin
case
ec
valu
compar
favor
amantadin
evalu
experiment
condit
bananin
chart
show
close
structur
relationship
previous
discuss
adamantan
deriv
repres
class
antivir
compound
uniqu
structur
signatur
incorpor
trioxaadamantan
moieti
coval
bound
pyridox
deriv
bananin
synthes
reaction
phloroglucinol
like
triketo
tautomer
form
aromat
aldehyd
catalyz
hydrochlor
acid
sodium
hydroxid
aqueou
solut
gener
acid
catalysi
use
due
degrad
pyridox
highli
basic
condit
alkalin
catalysi
use
reaction
aromat
aldehyd
vanillin
obtain
vanillinbananin
vbn
bananin
synthesi
driven
creation
highli
symmetr
trioxaadamantanetriol
tat
cage
system
prototyp
compound
tat
seri
vitamin
bananin
ban
iodin
subsequ
oxid
iodobananin
ibn
iodin
ibn
replac
variou
substitu
exemplifi
synthesi
adeninobananin
adn
use
activ
adenin
nucleobas
deriv
interestingli
ban
suscept
michael
addit
natur
product
eugenol
naohcatalyz
addit
lead
eubananin
eub
transform
cyclic
hemiket
condens
ansacompound
ansabananin
abn
inspir
ansamycin
rifamycin
geldanamycin
newer
agent
relat
function
chart
includ
norbornylamin
novel
bafilomycin
macrolid
antibiot
ici
advanc
clinic
trial
approv
clinic
use
chart
found
block
channel
express
xenopu
oocyt
howev
crossresist
amantadin
occur
compound
bafilomycin
specif
inhibitor
vacuolartyp
h
atpas
complet
abolish
acidifi
cell
compon
endosom
lysosom
influenza
b
virusinfect
uninfect
madindarbi
canin
kidney
mdck
cell
action
compound
unlik
amantadin
revers
sever
opportun
therapeut
intervent
disrupt
care
orchestr
role
ha
influenza
infect
one
strategi
explor
inhibit
cellular
enzym
respons
essenti
proteolyt
cleavag
ha
import
determin
pathogen
cell
tropism
howev
progress
area
confound
multitud
cellular
extracellular
trypsinlik
enzym
capabl
perform
step
influenza
viru
infect
nevertheless
trypsin
inhibitor
futhan
anticathepsin
b
igg
antibodi
shown
possess
influenzainhibitori
activ
vitro
set
quinon
identifi
specif
inhibitor
fusioninduc
conform
chang
ic
mm
hydroquinon
form
prove
potent
ic
mm
although
chemic
properti
make
unlik
drug
candid
compound
repres
first
new
mechanist
class
influenza
viru
inhibitor
demonstr
feasibl
prevent
conform
chang
ha
small
molecul
limit
complex
recent
flavon
contain
structur
element
common
also
postul
interfer
fusion
influenza
viral
endosom
membran
furthermor
report
noncompetit
inhibitor
influenza
viru
sialidas
ic
mm
host
cell
transcript
machineri
use
influenza
viru
polymeras
complex
viral
rna
transcript
cap
capmethyl
splice
viral
mrna
polymeras
transcript
complex
influenza
virus
consist
trimer
structur
complex
consist
transcriptas
capbind
protein
possibl
endonucleas
pa
essenti
cofactor
unknown
function
associ
polymeras
rna
templat
harbor
essenti
influenza
virusspecif
sequenc
motif
nucleoprotein
np
rna
bind
protein
requir
full
transcriptas
activ
polymeras
influenza
virus
contain
endonucleas
activ
cut
host
cell
mrna
approxim
nucleotid
cap
use
cap
oligonucleotid
primer
gener
cap
viral
mrna
endonucleas
uniqu
highli
conserv
target
present
influenza
virus
dival
metal
ion
requir
enzymat
catalysi
endonucleas
reaction
number
potenti
metal
ion
chelat
compound
describ
target
flutimid
isol
delitschia
confertaspora
select
inhibit
capdepend
transcriptas
influenza
b
virus
mdck
cell
flutimid
inhibit
influenza
viru
replic
ic
mm
exhibit
cytotoxictiy
concentr
mm
flutimid
fulli
substitut
contain
follow
crucial
group
nhydroxyimid
imin
exocycl
enamin
zgeometri
endocycl
imin
may
help
stabil
exocycl
enamin
via
extend
conjug
synthet
pathway
obtain
compound
unusu
structur
featur
outlin
scheme
nalkyl
leuomehcl
c
equimolar
amount
abromotertbutyl
acet
ch
pmethoxybenzyl
pmb
chlorid
tertbutyl
protect
group
correspond
ester
select
hydrolyz
tfa
acid
group
activ
nhydroxysuccinimid
produc
activ
ester
react
neutral
hydroxylamin
give
compound
subsequ
could
cycliz
nhydroxi
group
conveni
protect
mom
chlorid
afford
mom
ether
aldol
condens
isobutyraldehyd
lithium
hexamethyldisilazid
lhmd
c
exclus
produc
flutimid
advanc
hydroxi
intermedi
aldol
product
react
methanesulfonyl
chlorid
mscl
dipea
dmap
c
give
quantit
yield
correspond
mesyl
belimin
reaction
turn
challeng
final
reaction
mesyl
c
equiv
dbu
toluen
gave
combin
yield
ze
mixtur
olefin
respect
oxid
ddq
mixtur
ch
cl
h
gave
expect
oxid
product
moder
yield
due
decomposit
product
presum
caus
hydrat
subsequ
cascad
rearrang
reaction
final
deprotect
tfach
cl
gave
flutimid
select
inhibit
endonucleas
activ
influenza
b
virus
exampl
seri
acid
endonucleas
inhibitor
compound
show
antivir
activ
cell
cultur
influenza
b
virus
ic
mm
respect
appar
cytotox
effect
mdck
cell
concentr
mm
member
seri
show
antivir
activ
ic
mm
higher
nucleosid
analog
deoxyfluoroguanosin
appear
specif
inhibitor
influenza
transcriptas
activ
target
activ
site
polymeras
subunit
triphosph
show
competit
inhibit
gtp
vitro
incorpor
nucleosid
analog
place
gtp
influenza
viru
polymeras
lead
chain
termin
transcript
initi
seri
variou
substitut
fluororibosid
synthes
enzym
pentosyl
transfer
fluorouridin
differ
strain
influenza
b
virus
sensit
ic
rang
mm
chicken
embryo
fibroblast
cell
mm
mdck
cell
mean
pulmonari
viral
titer
influenza
b
mice
significantli
reduc
intraperiton
treatment
mgkg
hr
postinfect
compar
untreat
control
compound
also
appear
effect
amantadin
influenza
ribavirin
influenza
b
howev
prodrug
fluororibonucleosid
progress
beyond
preclin
develop
extract
product
plant
origin
provid
altern
sourc
substanc
virusinhibitori
activ
although
hardli
consid
purin
nucleosid
base
purport
cellular
enzym
recogn
nucleosid
base
convert
phosphoryl
metabolit
structur
similar
known
impdh
inhibitor
discuss
section
suggest
transform
monophosph
lead
reduct
gtp
pool
size
infect
cell
howev
inhibit
impdh
lower
ribavirin
anoth
interest
report
transcript
inhibitor
antisens
oligonucleotid
target
genom
antisens
nucleotid
stabil
chimera
format
dna
rna
dumbbel
structur
end
nucleotid
cytosin
alkyl
loop
synthes
antisens
oligonucleotid
complementari
influenza
viral
rna
polymeras
compon
administ
intraven
liposomeencapsul
form
mice
shown
significantli
prolong
surviv
infect
influenza
viru
dna
enzym
target
mrna
translat
initi
aug
region
influenza
viru
design
modifi
dna
enzym
one
two
phosphoramid
bond
termini
oligonucleotid
significantli
enhanc
nucleaseresist
modifi
dna
enzym
cleavag
activ
unmodifi
dna
enzym
determin
kinet
analys
reduc
influenza
viru
replic
determin
plaqu
format
dna
enzym
highli
specif
sinc
protect
effect
observ
influenza
b
viru
bibaraki
infect
mdck
cell
inhibit
inosin
monophosph
dehydrogenas
impdh
result
decreas
intracellular
proof
gtp
requir
synthesi
nucleic
acid
mechan
action
account
antiinfluenza
activ
compound
activ
sever
influenza
b
virus
mdck
cell
ic
valu
mgml
addit
compound
protect
mice
influenza
b
infect
administ
oral
immedi
sever
day
experiment
infect
howev
develop
discontinu
lack
clinic
efficaci
increas
patient
serum
uric
acid
level
ribavirin
virazol
synthet
guanosin
deriv
broad
spectrum
antivir
activ
sever
rna
viru
famili
sever
mechan
action
propos
antiinfluenza
viru
activ
ribavirin
among
imph
inhibit
see
inhibit
mrna
cap
format
inhibit
viruscod
rna
polymeras
necessari
initi
elong
viral
mrna
neuraminidas
inhibitor
interact
uniqu
albeit
late
target
viral
replic
cycl
releas
progeni
viru
particl
cell
fig
releas
viru
particl
cell
requir
action
virusassoci
neuraminidas
cleav
termin
nacetylneuramin
acid
sialic
acid
link
bond
galactos
influenza
receptor
respect
cleavag
need
viru
particl
releas
infect
cell
allow
viru
spread
cell
neuraminidas
inhibitor
prevent
releas
thu
trap
newli
form
viru
particl
cell
surfac
therebi
inhibit
viru
spread
oseltamivir
highli
water
solubl
phosphat
salt
trisubstitut
cyclohexen
ethylcarboxyl
claim
molecul
month
decemb
howev
chemistri
still
remain
challeng
sinc
synthesi
excess
review
latest
develop
document
origin
synthesi
start
shikim
acid
isol
illicium
verum
chines
star
anis
quinin
acid
isol
african
cinchona
tree
epoxid
seen
key
intermedi
convert
oseltamivir
phosphat
use
azidechemistri
allylamin
rout
tbutylaminediallylamin
rout
latter
would
allow
safe
scaleup
industri
purpos
due
avail
problem
natur
sourc
case
pandem
much
effort
paid
cheaper
easier
avail
synthes
desymmetr
protocol
outlin
scheme
base
enzymat
monohydrolysi
allci
meso
diester
optic
activ
monoacid
start
inexpens
phenol
ether
introduc
follow
bromin
dibromid
pdcatalyz
doubl
ethoxycarbonyl
furnish
isophal
diester
hydrogen
rualox
allci
mesodiest
high
select
yield
nearli
quantit
highli
select
cleavag
methyl
ether
group
use
situ
gener
tmsiodid
provid
mesodihydroxi
intermedi
readi
enzymat
desymmetr
use
pig
liver
esteras
ple
slightli
elev
temperatur
c
afford
desir
monoacid
high
yield
select
use
yamadacurtiu
degrad
introduc
result
format
oxazolidinon
follow
bocprotect
compound
obtain
heat
mixtur
toluen
trace
sodium
hydrid
way
effect
select
format
bond
simultan
cleavag
oxazolidinon
system
achiev
tfo
use
introduc
good
leav
group
function
final
introduc
via
n
use
sodium
azid
concomit
invers
configur
mild
alkalin
condit
azid
reduct
nacetyl
bocdeprotect
phosphat
salt
format
gave
final
product
overal
yield
recent
new
concept
obtain
oseltamivir
way
dielsald
approach
report
scheme
start
butadien
trifluoroethyl
acryl
presenc
sprolinederiv
catalyst
dielsald
reaction
carri
obtain
excel
yield
ammonolysi
produc
amid
quantit
iodolactam
use
knapp
protocol
gener
lactam
high
yield
follow
nprotect
boc
dehydroiodin
occur
cleanli
give
allyl
bromin
use
nbromosuccinimid
gener
treatment
cesium
carbon
quantit
afford
dien
ethyl
ester
novel
snbr
catalyz
bromoacetimid
reaction
complet
regioselect
stereoselect
convert
dien
bromodiamid
treatment
situ
gener
tetranbutylammonium
hexamethyldisilazan
furnish
nacetylaziridin
could
regioselct
convert
ether
reaction
cupric
triflat
catalysi
optim
final
remov
protect
group
afford
oseltamivir
scheme
synthesi
dielsald
reaction
synthet
strategi
prepar
zanamivir
origin
start
nacetylneuramin
acid
scheme
follow
protect
acid
function
peracetyl
gave
lewi
acidcatalyz
elimin
intramolecular
cycliz
reaction
yield
oxazol
deriv
turn
achiev
upon
treatment
trimethylsilylazid
azid
deprotect
follow
reduct
azid
function
yield
could
convert
desir
guanidin
deriv
recent
approach
zanamivir
report
start
dgluconodlacton
scheme
follow
reaction
dgluconodlacton
aceton
methanol
catalyt
amount
ptsoh
free
alcohol
function
benzyl
obtain
ester
correspond
alcohol
obtain
reduct
ester
lialh
subsequ
treatment
dessmartin
periodinan
gave
aldehyd
convert
imin
help
highli
select
syn
addit
allylmagnesium
bromid
amin
obtain
nacetyl
simultan
debenzyl
final
good
leav
group
alcohol
function
introduc
obtain
could
convert
aziridin
key
intermedi
reaction
nah
thf
use
nan
etohwat
presenc
nh
cl
allow
open
aziridin
ring
regioselect
less
hinder
posit
free
amino
function
acetyl
obtain
structur
confirm
xray
termin
olefin
effici
dihydroxyl
catalyt
oso
presenc
nmo
acetonewat
obtain
diol
primari
hydroxyl
group
diol
select
oxid
tempo
base
condit
result
acid
immedi
convert
correspond
ester
wherea
remain
secondari
alcohol
oxid
aketocarboxyl
acid
methyl
ester
treatment
hf
mecn
afford
sugar
deriv
turn
fulli
acetyl
follow
replac
aacetoxyl
group
chlorin
obtain
dbuinduc
elimin
reaction
afford
known
azid
intermedi
previous
describ
synthesi
zanamivir
famili
uloson
acid
provid
potenti
therapeut
lead
develop
inhibitor
correspond
enzym
zanamivir
transit
state
analog
acid
exhibit
high
inhibitori
activ
influenza
neuraminidas
na
approv
treatment
influenza
synthes
uloson
acid
analog
attract
consider
interest
recent
year
becom
current
research
topic
synthesi
compound
previous
review
compound
kind
hybrid
compound
oseltamivir
zanamivir
heterocycl
core
show
substitut
pattern
also
show
good
inhibitori
activ
mark
select
influenza
sialidas
compound
compound
synthes
evalu
properti
influenza
neuraminidas
inhibitor
benzoic
acid
deriv
design
aromat
sialic
acid
analog
potent
compound
larg
seri
tetra
substitut
benzoic
acid
deriv
test
vitro
show
ic
respect
neuraminidas
compound
highli
select
type
influenza
na
ic
mm
type
b
influenza
na
ic
mm
xray
structur
nacetylamino
benzoic
acid
complex
na
reveal
lipophil
side
chain
bind
newli
creat
hydrophob
pocket
form
movement
glu
interact
arg
wherea
guanidin
interact
neg
charg
pocket
creat
asp
glu
glu
siastatin
b
broad
spectrum
sialidas
inhibitor
isol
streptomyc
cultur
character
unusu
charg
distribut
zwitterion
resembl
nacetylneuramin
oxocarbenium
ion
put
intermedi
enzymecatalyz
reaction
may
account
effect
bind
sialidas
start
siastatin
b
acid
prepar
compound
exhibit
strong
inhibit
particularli
influenza
viru
neuraminidas
confer
vitro
vivo
antivir
efficaci
deriv
possess
side
chain
similar
oseltamivir
show
influenza
viru
neuraminidaseinhibitori
activ
mm
rang
synthes
via
hetero
dielsald
reaction
compound
thioisost
zanamivir
could
shown
thioisost
bioactiv
oxygen
counterpart
inhibitor
influenza
viru
sialidas
chart
n
contain
sialic
acid
chart
pnitrophenyl
pnp
molecular
geometri
close
nacetylneuramin
acid
hypothes
serv
simpl
mimic
possess
high
potenti
biochem
medicin
applic
hypothesi
evidenc
neuraminidas
inhibit
assay
use
pnitrophenyl
pnp
pnp
found
show
substanti
activ
multimer
compound
develop
potenti
second
gener
compound
intend
inhal
therapi
prophylaxi
influenza
viru
infect
significantli
antivir
activ
monom
zanamivir
also
show
longlast
protect
activ
test
mous
influenza
viru
infect
experi
furthermor
polyval
sialidas
inhibitor
bear
zanamivir
polylglutamin
backbon
describ
peramivir
potent
inhibit
neuraminidas
enzym
viru
vitro
inhibitori
concentr
ic
ae
nm
onsit
dissoci
studi
indic
peramivir
remain
tightli
bound
na
hr
wherea
zanamivir
oseltamivir
carboxyl
dissoci
rapidli
enzym
hr
addit
efficaci
studi
indic
singl
inject
peramivir
mgkg
compar
qd
day
cours
oral
administ
oseltamivir
mgkgday
prevent
lethal
influenza
model
singl
intramuscular
inject
peramivir
found
effect
treatment
influenza
viru
infect
may
provid
interest
lead
use
case
influenza
outbreak
compound
found
ic
valu
mm
neuraminidas
mm
superior
dana
seri
compound
function
group
mode
bind
guanidino
group
analog
observ
crystal
structur
zanamivir
influenza
neuraminidas
diethylamid
dipropylamid
group
show
good
inhibitori
activ
ic
mm
neuraminidas
form
modest
activ
ic
mm
neuraminidas
b
deriv
diethylamid
dipropylamid
also
investig
howev
less
activ
compound
without
group
chart
dimer
trimer
tetramer
influenza
neuraminidas
synthesi
peramivir
scheme
start
lactam
hydrolyz
methanol
hcl
result
amino
ester
reaction
boc
anhydrid
produc
compound
cycloaddit
compound
nitril
oxid
produc
phenyl
isocyan
triethylamin
gave
cycloadduct
isom
cycloadduct
isol
mixtur
isom
hydrogen
methanol
equival
amount
aqueou
hcl
presenc
pto
psi
give
amin
hydrochlorid
react
acet
anhydrid
give
correspond
nacetyl
deriv
compound
reaction
ether
hcl
gave
deblock
amin
compound
guanyl
pyrazol
carboxamidin
hydrochlorid
dmf
presenc
diisopropylethylamin
gave
correspond
guanidino
ester
hydrolysi
naoh
gave
desir
compound
novel
pyrrolidinebas
compound
evalu
studi
abil
inhibit
b
strain
influenza
viru
neuraminidas
enzym
assay
influenza
viru
replic
cell
cultur
effect
inhibit
influenza
b
strain
neuraminidas
inhibitor
constant
k
valu
nm
valu
compar
lower
k
valu
measur
oseltamivir
carboxyl
zanamivir
perform
coupl
reaction
tertbutyldimethylsiloxi
pyrrol
strityl
sulfenimin
triflic
acid
equiv
thfheptan
c
yield
desir
isom
introduct
cispropenyl
group
obtain
requir
stereoselect
transaddit
situ
gener
propenyl
cuprat
partial
reduct
hemiamin
dibalh
follow
convers
amethoxycarbam
treatment
ppt
methanol
reaction
compound
tmscn
presenc
compound
potent
na
inhibitor
seri
ic
mm
na
mm
na
b
xray
crystallograph
structur
bound
na
reveal
predict
interact
carboxyl
group
posit
charg
pocket
interact
trifluoroacetamino
residu
hydrophob
pocket
enzym
activ
site
surprisingli
ethyl
isopropyl
group
urea
functionalityinduc
conform
chang
turn
hydrophil
pocket
normal
accommod
triglycerol
side
chain
substrat
sialic
acid
induc
hydrophob
pocket
seri
zpropenylanalog
found
potent
inhibitor
b
neuraminidas
ic
mm
respect
wherea
ic
deriv
found
rang
mm
compound
found
potent
benzoic
acid
analog
seri
ic
mm
influenza
ic
mm
influenza
b
neuraminidas
novel
aand
bamino
acid
inhibitor
influenza
neuraminidas
bear
pyrrolidin
moieti
exhibit
k
valu
mm
rang
influenza
viru
neuraminidas
exhibit
weaker
activ
influenza
viru
b
neuraminidas
limit
optim
pyrrolidin
seri
result
compound
potent
acid
antiinfluenza
cell
cultur
assay
use
viru
pyrrolidin
analog
aor
bamino
group
replac
hydroxyl
group
weaker
inhibitor
respect
result
underscor
import
amino
group
interact
asp
tyr
side
chain
implic
antiinfluenza
drug
design
commerci
avail
convert
protect
dihydroxi
keton
via
standard
procedur
swernoxid
dihydroxyl
protect
bayervillig
rearrang
carri
obtain
undesir
methylen
lacton
decompos
complet
treatment
aluminum
oxid
follow
prepar
iodolacton
treatment
k
co
afford
key
intermedi
deprotect
subject
oxid
ringopen
provid
desir
thf
deriv
convert
oxim
reduct
catalyt
hydrogen
presenc
bocanhydrid
gave
mixtur
two
separ
acetylamino
deriv
baselabil
could
select
hydrolyz
yield
monoacid
protect
group
group
obtain
hydrolyz
get
convert
bromomethyl
keton
moieti
via
diazomethyl
keton
condens
formamidin
liquid
ammonia
introduc
imidazol
moieti
upon
deprotect
desir
compound
afford
ic
valu
compound
na
nm
respect
less
potent
pyrrolidin
analog
na
b
compound
less
potent
ic
nm
respect
defensin
low
molecular
weight
antimicrobi
peptid
produc
phagocyt
variou
epitheli
locat
includ
lung
trachea
broad
spectrum
activ
varieti
pathogen
includ
bacteria
fungi
virus
defensin
activ
variou
envelop
virus
includ
influenza
peptid
bind
microbi
surfac
induc
format
membran
pore
defensin
could
therefor
inhibit
infect
influenza
disrupt
envelop
extracellular
viral
particl
defensin
present
airway
human
b
defensin
also
chemotact
dendrit
cell
memori
cell
may
therefor
stimul
adapt
immun
respons
recombin
product
defensin
low
molecular
weight
antimicrobi
peptid
attract
area
antivir
research
broad
spectrum
activ
agent
potenti
modul
host
defens
function
short
interf
rna
sirna
specif
conserv
region
influenza
viru
gene
found
reduc
viru
product
lung
infect
mice
sirna
given
intraven
iv
complex
polyc
carrier
either
initi
viru
infect
deliveri
sirna
specif
highli
conserv
region
nucleoprotein
acid
polymeras
significantli
reduc
lung
viru
titer
influenza
virusinfect
mice
protect
anim
lethal
challeng
protect
specif
mediat
antivir
interferon
respons
influenzaspecif
sirna
treatment
broadli
effect
protect
anim
lethal
challeng
highli
pathogen
avian
influenza
virus
subtyp
specif
sirnawould
effect
influenza
could
readili
predict
equal
effect
result
obtain
specif
sirna
sar
sever
acut
respiratori
syndrom
coronaviru
compar
situat
phosphorothio
oligonucleotid
pson
ie
rep
pson
offer
potenti
administ
aerosol
prophylaxi
therapi
influenza
infect
similarli
antisens
phosphorodiamid
morpholino
oligom
arppmo
could
pursu
potenti
treatment
influenza
viru
infect
sever
drug
avail
could
use
either
alon
combin
treatment
prophylaxi
therapi
pandem
influenza
whether
avian
human
viru
infect
includ
adamantan
amin
e
deriv
ie
amantadin
neuraminidas
inhibitor
ie
oseltamivir
ribavirin
interferon
combin
differ
antivir
act
influenza
differ
stage
viral
replic
could
import
area
research
futur
combin
strategi
prove
clinic
success
treatment
hiv
infect
